Trial reportNature communications2022
molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history.
Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00128661 (A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.
Who cites it
33 citing papers in PubMed, 59 citations in OpenAlex.
- Functionalized polysaccharides for infection-resistant and regenerative therapies in gynecology.International journal of pharmaceutics: X · 2026Review
- Article
- Bacterial vaginosis in microscopic examination of Pap smears in patients with high-risk HPV is associated with viral persistence and cytological progression in a longitudinal study.Infectious agents and cancer · 2026Article
- The impact of gut microbiota on cervical cancer and precancerous lesions: neglected status, mechanisms, challenges, and a call to action.Frontiers in immunology · 2026Review
- Dynamic chemokine profiles in cervical mucus during healthy pregnancy: IP-10 and MIP-1β as potential biomarkers of gestational immune adaptation.Frontiers in immunology · 2026Article
- From dysbiosis to mechanisms: Why cervicovaginal microbiome-HPV studies must catch up with biology.PLoS pathogens · 2025Article
- Natural Molecules, Nutraceuticals, and Engineered Nanosystems: A Comprehensive Strategy for CombatingMicroorganisms · 2025Review
- Vaginal Microbiome and Functional Pathway Alterations in Preterm Premature Rupture of Membranes Revealed by 16S rRNA Sequencing.Life (Basel, Switzerland) · 2025Article
- Shallow shotgun metagenomic sequencing of vaginal microbiomes with the Oxford Nanopore technology enables the reliable determination of vaginal community state types and broad community structures.BMC microbiology · 2025Article
- Drug and therapeutic intravaginal delivery targeting diseases in the female reproductive tract: A mathematical modeling perspective.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- Inferred bi-directional interactions between vaginal microbiota, metabolome and persistent HPV infection accompanied by high-grade cervical intraepithelial neoplasia.BMC microbiology · 2025Article
- Vaginal Microbiota and Local Immunity in HPV-Induced High-Grade Cervical Dysplasia: A Narrative Review.International journal of molecular sciences · 2025Review
- Sexually transmitted human papillomavirus and related sequelae.Clinical microbiology reviews · 2025Review
- Article
- Association between changes in genital immune markers and vaginal microbiome transitions in bacterial vaginosis.Scientific reports · 2025Article
- Viral and immune dynamics of genital human papillomavirus infections in young women with high temporal resolution.PLoS biology · 2025Observational
- Article
- A Narrative Review of the Putative Etiologic Role and Diagnostic Utility of the Cervicovaginal Microbiome in Human Papillomavirus-Associated Cervical Carcinogenesis.Journal of medical virology · 2024Review
- Ceragenins Prevent the Development of Murine Vaginal Infection Caused byPharmaceuticals (Basel, Switzerland) · 2024Article
- Temporal composition of the cervicovaginal microbiome associates with hrHPV infection outcomes in a longitudinal study.BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 3 countries.
Funding
Abstract
Bacterial vaginosis (BV) is a highly prevalent condition that is associated with adverse health outcomes. It has been proposed that BV's role as a pathogenic condition is mediated via bacteria-induced inflammation. However, the complex interplay between vaginal microbes and host immune factors has yet to be clearly elucidated. Here, we develop molBV, a 16 S rRNA gene amplicon-based classification pipeline that generates a molecular score and diagnoses BV with the same accuracy as the current gold standard method (i.e., Nugent score). Using 3 confirmatory cohorts we show that molBV is independent of the 16 S rRNA region and generalizable across populations. We use the score in a cohort without clinical BV states, but with measures of HPV infection history and immune markers, to reveal that BV-associated increases in the IL-1β/IP-10 cytokine ratio directly predicts clearance of incident high-risk HPV infection (HR = 1.86, 95% CI: 1.19-2.9). Furthermore, we identify an alternate inflammatory BV signature characterized by elevated TNF-α/MIP-1β ratio that is prospectively associated with progression of incident infections to CIN2 + (OR = 2.81, 95% CI: 1.62-5.42). Thus, BV is a heterogeneous condition that activates different arms of the immune response, which in turn are independent risk factors for HR-HPV clearance and progression. Clinical Trial registration number: The CVT trial has been registered under: NCT00128661.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.